Hongjiao Geng

Hongjiao Geng

Auto-generated profile, based on publicly available information

Hongjiao Geng

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Dongcheng District, Beijing, 100700, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
HGHongjiao Geng
Hongjiao Geng
LZLidan Zhang
Lidan Zhang
XCXin Cui
Xin Cui
CZCheng Zhang
Cheng Zhang
YXYanming Xie
Yanming Xie
Cerebral infarction is the second leading cause of death and the third most common cause of disability. The use of anti-platelet aggregation drugs is prone to bleeding, liver and kidney damage, gastrointestinal reactions, and is not suitable for patients to take for a long time. Xuesaitong oral preparations (XSTOP), a traditional Chinese medicine formula, has shown therapeutic effect on treating cerebral infarction based on the clinical practice and pharmacological mechanism. The study aims to evaluate the effectiveness and safety of XSTOP combined with conventional treatment (CT) in treatment of acute cerebral infarction (ACI), and to provide the reliable evidence for clinical application. We performed a literature search in Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, PubMed, EMBASE, Cochrane Library and Web of Science from their inceptions to August 2021. Systematic searches for randomized controlled trials (RCTs) of XSTOP in treatment of ACI. Odds ratio (OR) or mean difference (MD) with their 95% confidence interval was calculated between with and without XSTOP therapy. Cochrane risk of bias tool was used to evaluate the methodological quality of the included trials. Eight RCTs involving 827 patients were included in this meta-analysis. By comparing XSTOP plus conventional treatment with conventional treatment alone, the meta-analysis gave the following results: (1) Total effective rate (OR = 4.53, 95% CI[2.85, 7.19], P < 0.0001); (2) National Institutes of Health Stroke Scale (NIHSS) score (MD = -3.22, 95% CI[-4.52, -1.92], P<0.00001); (3) Plasma viscosity (PV) (MD = -0.74, 95%CI [-0.96, -0.51], P<0.00001), hole blood high-cut viscosity (HBV) (MD = -0.63, 95%CI [-0.73, -0.53], P = 0.84), whole blood low-cut viscosity (LBV) (MD = -0.37, 95%CI [-0.56, -0.19], P = 0.96), fibrinogen (FIB) (MD = -23.78, 95%CI [-28.57, -18.99], P = 1.00), hematocrit (Hct) (MD = -2.76, 95%CI [-3.16, -2.36], P = 0.96); (4) China Stroke Scale (CSS) score (MD = -6.53, 95% CI[-9.07, -3.99], P<0.00001); (5) No significant adverse reactions were reported; (6) The evidence was downgraded to "very low" quality, according to GRADE system. XSTOP plus CT is conditional recommended to improve the total effective rate, NIHSS score, PV, CSS score, and no serious adverse reactions were noted. The GRADE assessment indicates that the overall certainty quality of evidence is very low. Further large-scale, well-designed and high-quality RCTs are needed to confirm the positive results. As all studies included were conducted in China. It is unclear if the findings of this meta-analysis could be generalized to other populations.

14 January 2021 in Research Square
Verified
Preprint
Open access
PDF file
HGHongjiao Geng
Hongjiao Geng
RWRuili Wei
Ruili Wei
ZWZhifei Wang
Zhifei Wang
YXYanming Xie
Yanming Xie
ZLZhishuai Liu
Zhishuai Liu
Background: Although we have made tremendous medical advances in recent decades in vaccine and supportive therapies, the treatment of herpangina has not experienced such rapid advancement. Xiyanping injection(XYP) is a Chinese prescription with andrographolide as the main components. XYP shows strong inhibitory effects against enterovirus 71 virus,and existence of dose-response relationships in pharmacology studies. However, herpangina still lack specific therapeutics. The present study aimed to demonstrate the “real-world” experiences of herpangina in China using XYP therapy,to provide a basis for treatment of herpangina in children. Methods: We analyzed data of patients (≤70 years) diagnosed with herpangina and used XYP between October 2006 to October 2016 from the large electronic data warehouse (EDW), a multiple sources including hospital information system(HIS) data of “tertiary grade A hospitals” in China. Statistical analyses were performed by SAS9.2 and R.25 software. We present the following article in accordance with the STROBE Statement reporting checklist. Results: A total of 3423 patients of herpangina were retrieved for the analysis in this study. The mean age of the patient population was 2.66 years. Herpangina patients are often with multiple diagnosis, of which hand-foot-and-mouth disease(HFMD), bronchopneumonia and febrile seizure present a higher probability. Antibiotics were the most prescribed (17.61%) except for XYP, followed by ascorbate (10.40%). Conclusions: This study is the first comprehensive retrospective review of herpangina for XYP that has been used in a clinical setting. The present findings of clinical characteristics are fairly consistent with previous clinical studies. Clinical medication use of herpangina were basically in accordance with Expert Consensus of Herpangina in China(2019).Meanwhile, there are abuse problems of antibiotics and antivirals. Despite the underlying mechanisms in antibacterial and antiviral of XYP, the exact clinical efficacy is yet to be revealed. The efficacy and safety of XYP with Western medicines has not been studied.